USANA Health Sciences

USANA Health Sciences, Inc. develops and manufactures nutritional, personal care and weight-management products. It operates under the following segments: USANA Nutritionals, USANA Foods, Personal Care and Skincare, and All Other. The firm's brands include Procosa and MagneCal D. The company was founded by Myron W. Wentz in September 1992 and is headquartered in Salt Lake City, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

USANA Health Sciences addresses challenges, eyes growth through cost management

USANA Health Sciences navigated a challenging operating environment by focusing on cost management, product demand trends, and growth strategies. Despite facing headwinds in China and Southeast Asia, the company remains resilient and poised for opportunities in new markets and acquisitions.

USANA Health Sciences reports solid Q1 results amid global challenges

USANA Health Sciences delivered strong Q1 results amidst global challenges, driven by robust demand for health products.
Strategic leadership transition and focus on cost management position the company for sustained growth and operational efficiency.
Opportunities in China market, new market launches, and enhanced customer engagement strategies offer avenues for future expansion.

USANA Health Sciences exceeds Q2 expectations, eyes India expansion

USANA Health Sciences delivered strong Q2 results with a focus on sustainable growth strategies and expansion into new markets. Challenges include tough year-over-year comparisons and cash flow impact from accrued liabilities.

USANA Health Sciences addresses challenges, eyes India expansion for growth

USANA Health Sciences navigated challenges in Q3 2023 with a focus on addressing operational hurdles and driving growth through strategic initiatives. The company's restructuring and expansion into India signal a commitment to long-term success and capitalizing on emerging opportunities.

USANA Health Sciences exceeds Q4 expectations, eyes global growth

USANA Health Sciences delivered strong performance in Q4 2023, driven by growth in Greater China and a solid financial position. While facing challenges such as currency fluctuations and market-specific issues, the company is well-positioned to capitalize on opportunities through strategic initiatives and market tailoring. By focusing on sustainable growth and innovation, USANA aims to further strengthen its market presence and drive profitability.

USANA Health Sciences reports mixed Q1 results, eyes growth strategies

USANA Health Sciences faced mixed results in Q1 2024, with Mainland China driving growth while other markets struggled. The company is addressing challenges through market-specific incentives and focusing on future strategies like product development and localization.

USANA Health Sciences adapts to market challenges with strategic focus

USANA Health Sciences navigated macroeconomic challenges by implementing strategic initiatives and restructuring its commercial team.
The company's focus on product innovation, market expansion into India, and leadership additions signal a commitment to sustainable success.
While facing challenges in market conditions, USANA aims to leverage opportunities like M&A activities and accelerated product development for growth.

USANA Health Sciences adapts strategies to drive growth amid challenges

USANA Health Sciences faced challenges in Q3 with lower-than-expected net sales, particularly in China, but is implementing strategies to boost performance.
The company's strengths in product innovation, streamlined development processes, and strong product lineup position it well for future growth.
Addressing challenges such as decreased average spend and revised guidance presents opportunities for USANA to enhance revenue and market presence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arrow Electronics

Herbalife

Rightmove PLC

Tech Data

Z Holdings Corp

A Screened List Of High-Quality Stocks - July 2020

eXp World Holdings Inc

Fortinet

Logitech

Here are four excellent liquid stocks, including Fortinet (FTNT), that can contribute to making an outstanding portfolio for yield-seeking investors.

Power Your Portfolio With These 4 Top-Ranked Liquid Gems

Hartford Financial Services Group

Herman Miller

MSCI

Akamai Technologies

With the economy reopening, it's difficult to determine the direction the market will go – especially with unemployment claims surpassing 40 million. With that in mind, our AI has determined the best stocks to buy today.

Top Buys As Stocks Rally On Easing Of Coronavirus Lockdown

AAON

Dorman Products

Benjamin Graham recommended picking U.S.-listed equities of companies that have a current ratio higher than 2 and more working capital than long-term debt, as this suggests robust balance sheets.

A Trio of High-Quality Stocks for the Value Investor

A Relative Strength Rating upgrade for USANA Health Science shows improving technical performance.
The post USANA Health Science Sees RS Rating Rise To 90, Trading Near Its Buy Point appeared first on Investor's Business Daily.

USANA Health Science Sees RS Rating Rise To 90, Trading Near Its Buy Point

USANA Health Sciences Inc. (USNA) Q1 2020 Results - Earnings Call Transcript

USANA Health (USNA) delivered earnings and revenue surprises of 115.79% and 20.97%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

USANA Health Sciences (USNA) Tops Q1 Earnings and Revenue Estimates

USANA Health (USNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: USANA Health Sciences (USNA) Q1 Earnings Expected to Decline

International Money Express Inc.

Kirkland Lake Gold

Tandem Diabetes Care

Four top-ranked liquid stocks that investors can bank on for fat returns.

4 Best-Ranked Liquid Stocks for Alluring Returns

MagnaChip Semiconductor

Trupanion

Here are four excellent liquid stocks that can contribute to making an outstanding portfolio for yield-seeking investors.

4 Top-Ranked Liquid Bets - to Build a Successful Portfolio

USANA Health Sciences, Inc. (USNA) CEO Kevin Guest on Q4 2019 Results - Earnings Call Transcript

Usana Health Sciences Inc. USNA, +4.62% shares rallied in the extended session Tuesday after the nutritional supplements company reported quarterly results that topped Wall Street expectations and forecast a strong outlook.

Usana stock rallies more than 20% on earnings, outlook

Brinker International

Eagle Bancorp

Green Dot

Hawaiian Hlds

Rush Enterprises

Companies that are growing their earnings are often good investments because they can return a solid profit to investors.

6 Bargain Stocks Growing Earnings

Sales and earnings fell for the global cellular nutrition company in Q3, but it still managed to beat Wall Street expectations.

What's Behind USANA Health Sciences' Q3 Earnings Beat

USANA Health Sciences, Inc. (USNA) CEO Kevin Guest on Q3 2019 Results - Earnings Call Transcript

USANA Health Sciences, Inc. (USNA) CEO Kevin Guest on Q2 2019 Results - Earnings Call Transcript

The nutrition company reported mainly bad news with its Q2 earnings update.

What You'll Want to Know About USANA Health Sciences' Q2 Earnings

Broadcom

Electronic Arts

Find out what made these stocks miss today's rally.

Why Electronic Arts, USANA Health Sciences, and Broadcom Slumped Today

USANA Health Sciences (NYSE: USNA) shares are trading sharply lower after the company cut its FY2019 EPS and sales guidance below analyst estimates.

USANA Issues Concerning Guidance, Shares Slammed

USANA Health Sciences, Inc. (USNA) CEO Kevin Guest on Q1 2019 Results - Earnings Call Transcript

News for USANA Health Sciences Stock (USNA)